Gryphon Creative

Gryphon Bio has developed a novel panel of blood biomarkers designed to enable early detection and monitoring of traumatic brain injury and Alzheimer’s disease. The company’s technology leverages over two decades of proteomic research by its co-founders. It has initiated observational clinical studies at multiple U.S. and international sites to validate the utility of these tests in real-world settings. The company has received more than $13 million in non-dilutive government grant funding to support its research and development efforts. Key leadership includes experienced executives from diagnostics and medtech backgrounds, with a focus on bringing innovative diagnostic solutions to market for critical unmet needs in neurology.